Video Transcription
Pau Rodriguez 00:01
When we started the company, we thought about how we could use AI so that every hospital in the world could have the best diagnostic capabilities, so every patient, no matter where they went, would have access to the right treatment. We decided to focus on stroke because, in stroke, time is brain; every minute until you get the treatment increases the risk of disability and death. The most effective treatment for stroke is the endovascular treatment, which basically consists of removing the clot from the brain. However, the problem is that only one in 14 patients has access to the endovascular treatment, and there are many factors contributing to that. Let's look at the workflow to understand some of them. When a patient goes to a hospital, they will always get a basic CT scan to rule out an MRI. But they will need to inject contrast and do contrast imaging to see the vascularity of the brain and assess how damaged the brain is to then determine whether they should transfer the patient or not. The problem is that half of the hospitals worldwide don't have access to contrast medical imaging, and even if they had access, it would reduce the time to treatment. So what we've built is an AI software that is capable of assessing stroke treatment directly from a non-contrast CT, which is universally available, increasing the opportunity for endovascular treatments and reducing time to treatment. Now, if we only increased the current endovascular treatments by 10%, this would lead to thousands of lives saved and disabilities prevented, resulting in savings for healthcare systems and potential reimbursement for U.S. hospitals. In terms of market, we expect a market of a couple of billion only in the stroke space in AI, which represents 10% of the total estimated market in medical imaging AI. Now, why are we unique? We are the only company in the world that has received a CE Mark Class II to detect large vessel occlusions from a non-contrast CT. It also includes intracranial hemorrhage or large vessel occlusion with non-contrast. But even more important than the AI is to deliver and facilitate the coordination among healthcare systems. Instead of developing another communication system, we've integrated our technology into Microsoft Teams, enabling a CT scan viewer within Teams. The image will go from the CT scan to our cloud, we will process it, and we will be able to deliver this result. We don't want another communication system; we need to speed things up. We need to make it scalable, and that's certainly very important. In the next few weeks, we expect FDA clearance for LVO with non-contrast, and the performance we submitted is 50% higher than our competitors. On top of that, we have three other products that have been clinically validated and are in research mode, such as assessing how damaged the brain is, the infarct volume, assessing more distal occlusions, and also the posterior circulation, as well as the intracranial hemorrhage volume. But how do we position ourselves differently from our competitors? Let's look at the landscape. Most of the players in the field started by focusing on contrast imaging and building a communication system to be this platform. Now they are partnering with different pharma companies to build other products beyond stroke, but if you really want to enable stroke treatments, you need to enable non-contrast imaging. So we are building the best AI in the world for non-contrast, and we're leveraging Microsoft Teams as the communication system. We don't want to be in 2,000 hospitals; we want to be in 100,000 hospitals, and we believe this is the best way to do so. We're already installed in several groups of hospitals in the U.S. and Europe. We've done several publications, we've won international AI competitions, and by the end of the year, we expect FDA clearance. We anticipate having multi-year contracts. We're negotiating a distribution agreement with a leading medical device company, and potentially we may license one of our technologies to several players in the field. On top of that, we're building a pipeline focused on stroke that goes from the admission of the patient to personalized medicine to the follow-up of these patients. Our board is constituted by repeat venture capitalists. We also have a very influential key opinion leader. We recently brought in Susan as an independent chair of the board, who is an experienced CEO in the U.S., and Christian, who is a successful entrepreneur here in Spain. We have the commitment and support of the most reputed KOLs that have already transformed the stroke space and want to enable more treatments. Currently, we're a team of 22 people managing all the R&D and customer success. We've brought in advisors and commercial leaders from some of our competitors to help us define our go-to-market strategy. For now, we've raised $10 million, and now we're looking for $7.5 million that will allow us to execute these commercial deals we're working on and reach $3 to $5 million in revenue. Finally, our goal is that every single patient, no matter the hospital they go to, has access to the right treatment. So thank you very much. Thank you.
